Evaluating Investigational Drug PLN-74809 in Participants with Primary Sclerosing Cholangitis (PSC) and Suspected Liver Fibrosis (INTEGRIS-PSC)

Recruiting
18 years - 75 years
All
Phase 2
5 participants needed
1 Location

Brief description of study

The purpose of this study is to determine the safety and tolerability of an experimental medication PLN-74809 to treat primary Sclerosing Cholangitis (PSC), a rare, long-term liver disease affecting the bile ducts (small tubes) inside and outside the liver. Participants will visit the study center 8 times within 22 weeks. Compensation maximum amount you will be paid is $700.

Detailed description of study

The purpose of this study is to determine the safety and tolerability of an experimental medication PLN-74809 to treat primary Sclerosing Cholangitis (PSC), a rare, long-term liver disease affecting the bile ducts (small tubes) inside and outside the liver. Participants will visit the study center 8 times within 22 weeks. Compensation maximum amount you will be paid is $700.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Sclerosing Cholangitis, PSC, liver
  • Age: 18 years - 75 years
  • Gender: All
Updated on 04 Aug 2024. Study ID: 843393

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center